Stock Taper
EARNINGS CALL ARCHIVE 4 CALLS ON FILE
LGND — Ligand Pharmaceuticals Incorporated
NASDAQ
FULL STOCK PAGE →

Q4 2025 Earnings Call Summary

FEB 26, 2026
REVENUE
$59.7M -48.3%
NET MARGIN
75.1% -26.5 PTS
EPS
$2.27 -62.1%
FREE CASH FLOW
$45.8M +250.6%

No summary has been written for this call yet.